Bristol-Myers Squibb on Monday announced the submission of a New Drug Application to the Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic hepatitis B. A similar marketing application was filed with the European Medicines Evaluation Agency. Entecavir is an oral antiviral drug designed to selectively inhibit the hepatitis B virus by blocking all three steps in the viral replication process. A decision by the FDA may come as soon as next spring. Hepatitis A and B are sexually transmitted diseases that represent particular health risks for sexually active gay and bisexual men. The Gay and Lesbian Medical Association urges all gay men to be vaccinated against the viruses. Hepatitis B can lead to cirrhosis of the liver, liver cancer, and death. It's estimated that hepatitis B infects from 140,000 to 320,000 Americans each year, and 1.25 million have chronic hepatitis B infections.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















